What does aqst stand for?
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced, in response to Indivior PLC’s press release issued earlier today...
Where can I buy aqst shares?
Shares of AQST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What price target do analysts set for aqst?
What price target have analysts set for AQST? 5 brokerages have issued twelve-month price targets for Aquestive Therapeutics' stock. Their forecasts range from $7.00 to $30.00. On average, they anticipate Aquestive Therapeutics' share price to reach $14.67 in the next year.
How much did aqst raise in its IPO?
(AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.
See more
Is AQST a good stock to buy?
Aquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Will Aquestive Therapeutics stock go up?
Stock Price Forecast The 5 analysts offering 12-month price forecasts for Aquestive Therapeutics Inc have a median target of 8.00, with a high estimate of 17.00 and a low estimate of 7.00. The median estimate represents a +716.33% increase from the last price of 0.98.
Will AQST get FDA approval?
Aquestive opened the IND for AQST-109 after receiving FDA clearance in February 2022. The Company anticipates conducting an end of Phase 2 meeting with the FDA and commencing the pivotal PK study in the second half of 2022.
Is iQSTEL a good stock to buy?
If you are looking for stocks with good return, iQSTEL Inc can be a profitable investment option. iQSTEL Inc quote is equal to 0.400 USD at 2022-06-14. Based on our forecasts, a long-term increase is expected, the "IQST" stock price prognosis for 2027-06-04 is 73.556 USD.
Is Aquestive Therapeutics a buy right now?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 3 bu...
When is Aquestive Therapeutics' next earnings date?
Aquestive Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast fo...
How were Aquestive Therapeutics' earnings last quarter?
Aquestive Therapeutics, Inc. (NASDAQ:AQST) released its quarterly earnings results on Tuesday, May, 3rd. The company reported ($0.32) earnings per...
What guidance has Aquestive Therapeutics issued on next quarter's earnings?
Aquestive Therapeutics issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period....
What price target have analysts set for AQST?
3 equities research analysts have issued twelve-month target prices for Aquestive Therapeutics' shares. Their forecasts range from $8.00 to $17.00....
Who are Aquestive Therapeutics' key executives?
Aquestive Therapeutics' management team includes the following people: Mr. A. Ernest Toth Jr. , Sr. VP & CFO (Age 63, Pay $679.9k) Mr. Daniel Ba...
Who are some of Aquestive Therapeutics' key competitors?
Some companies that are related to Aquestive Therapeutics include OptiNose (OPTN) , CymaBay Therapeutics (CBAY) , Omeros (OMER) , XBiotech (XBI...
What other stocks do shareholders of Aquestive Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Ther...
When did Aquestive Therapeutics IPO?
(AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 pe...
About Aquestive Therapeutics
Headlines
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
Aquestive Therapeutics (NASDAQ:AQST) Frequently Asked Questions
Did You Acquire (AQST) Before December 2, 2019? Should Aquestive Therapeutics Management be Held Accountable for Investors Losses? Contact Johnson Fistel
Component Grades
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aquestive Therapeutics stock. View analyst ratings for Aquestive Therapeutics or view top-rated stocks.
AQST POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
AQST Stock Summary
AQST scores best on the Growth dimension, with a Growth rank ahead of 90.61% of US stocks.
AQST Valuation Summary
Aquestive Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 4.62% of US listed stocks.
AQST's Quality Factors
AQST's price/sales ratio is 4.3; this is 13.16% higher than that of the median Healthcare stock.
Latest AQST News From Around the Web
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Continue Researching AQST
Below are the latest news stories about Aquestive Therapeutics Inc that investors may wish to consider to help them evaluate AQST as an investment opportunity.
Signals & Forecast
Want to see what other sources are saying about Aquestive Therapeutics Inc's financials and stock price? Try the links below:
Support, Risk & Stop-loss
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Aquestive Therapeutics Inc.
Is Aquestive Therapeutics Inc. stock A Buy?
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Insiders are neutral selling more shares than they are buying in Aquestive Therapeutics Inc
Aquestive Therapeutics Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Golden Star Signal
In the last 100 trades there were 3.65 million shares bought and 4.01 million shares sold. The last trade was done 180 days ago by Kendall Keith J who sold 1 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Aquestive Therapeutics' (AQST) stock news
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Aquestive's stock price forecast
Aquestive has decided to revise the stock sale agreement it entered into with Piper Sandler in September 2019. The revised agreement, disclosed on March 26, allows the company to sell as many shares as it wants to raise cash for its operations.
Aquestive stock looks like a good investment
Aquestive shares have traded in the range of $1.75–$9.47 over the past year. Although the stock is up nearly 160 percent from its low, it has been sliding recently with its losses in the past month coming to 15 percent. That's fueling investors' curiosity about AQST's stock price forecast.
Can Reddit investors repeat the GameStop frenzy in AQST stock?
Aquestive has focused on treatment areas with significant unmet needs, which suggests potentially huge and long-term demand for its drugs. The company continues to expand its product pipeline, which should open a bigger revenue opportunity.
Aquestive (AQST) stock is a buy on the dips
Retail investors on Reddit community WallStreetBets drove GameStop (GME) stock up about 2,000 percent in early 2021 and made huge profits. They identified that GME stock was heavily shorted and knew driving up the price would force the funds betting against it to rush to cover their positions.
Where to buy Aquestive (AQST) stock
The more than 53 percent pullback in Aquestive stock from its peak has opened an opportunity for bargain hunters to enter at a discount. The stock seems to be a good deal now considering that AQST's stock forecast points to massive upside potential. Keep in mind that penny stocks are usually volatile.
